Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform
Key Takeaways Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.